Recently, a comment from the Society for Immunotherapy of Cancer indicated that tumor PD-L1 expression is generally correlated with a better response in R/M HNSCC patients who receive anti-PD-1/PD-L1 ICI treatment. The gene discussed is PDCD1; the disease is neoplasm.